ARTICLE | Clinical News
Progen starts PI-88 HCC Phase II
July 14, 2004 7:00 AM UTC
Progen (ASX:PGL; PGLAF) began a Phase II trial in Taiwan comparing two doses of its PI-88 to no treatment following primary tumor resection in about 340 hepatocellular carcinoma (HCC) patients. The pr...